RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform.
about
Oligonucleotide therapeutic approaches for Huntington diseasemRNA 3'end processing: A tale of the tail reaches the clinicAdvanced In vivo Use of CRISPR/Cas9 and Anti-sense DNA Inhibition for Gene Manipulation in the BrainBioengineering of noncoding RNAs for research agents and therapeuticsNon-coding landscapes of colorectal cancerTherapeutic Oligonucleotides Targeting Liver Disease: TTR AmyloidosisNew treatment strategies for hepatitis C infectionProspects for nucleic acid-based therapeutics against hepatitis C virusAnti-inflammatory therapy in chronic disease: challenges and opportunitiesNanoparticle delivery of antisense oligonucleotides and their application in the exon skipping strategy for Duchenne muscular dystrophyArgonaute-dependent small RNAs derived from single-stranded, non-structured precursorsSplicing therapy for neuromuscular diseaseModulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approachesPartial Hepatectomy Induced Long Noncoding RNA Inhibits Hepatocyte Proliferation during Liver RegenerationReversal of phenotypes in MECP2 duplication mice using genetic rescue or antisense oligonucleotides.An Exocyclic Methylene Group Acts As a Bioisostere of the 2′-Oxygen Atom in LNASynthesis, Improved Antisense Activity and Structural Rationale for the Divergent RNA Affinities of 3′-Fluoro Hexitol Nucleic Acid (FHNA and Ara-FHNA) Modified OligonucleotidesInsights from Crystal Structures into the Opposite Effects on RNA Affinity Caused by the S - and R -6′-Methyl Backbone Modifications of 3′-Fluoro Hexitol Nucleic AcidThe Conformationally Constrained N -Methanocarba-dT Analogue Adopts an Unexpected C4′- exo Sugar Pucker in the Structure of a DNA HairpinStructure and nuclease resistance of 2′,4′-constrained 2′-O-methoxyethyl (cMOE) and 2′-O-ethyl (cEt) modified DNAsTargeting mRNA for Alzheimer's and related dementias.Complexities of TGF-β targeted cancer therapy.Directional and reoccurring sequence change in zoonotic RNA virus genomes visualized by time-series word countKnocking down disease: a progress report on siRNA therapeuticsRNA-targeted Therapeutics for ALSThe role of splicing factors in deregulation of alternative splicing during oncogenesis and tumor progressionEpigenome-based personalized medicine in human cancerUnlocking the sugar "steric gate" of DNA polymerasesTargeting RNA polymerase primary σ70 as a therapeutic strategy against methicillin-resistant Staphylococcus aureus by antisense peptide nucleic acidAllele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patientsIntegrated Safety Assessment of 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human VolunteersRibonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotidesRNA therapeutics: RNAi and antisense mechanisms and clinical applicationsSynthetic oligonucleotides recruit ILF2/3 to RNA transcripts to modulate splicingHsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2'-modifications and enhances antisense activitySilencing disease genes in the laboratory and the clinicRNA phase transitions in repeat expansion disorders.Intracellular delivery of an antisense oligonucleotide via endocytosis of a G protein-coupled receptor.Transcriptional regulation of translocator protein (Tspo) via a SINE B2-mediated natural antisense transcript in MA-10 Leydig cells.Pathological impact of SMN2 mis-splicing in adult SMA mice
P2860
Q22306293-47E7F2C5-1C91-4465-BC9C-63C917805453Q24601240-6A212FC3-A9AA-4FA4-B9F3-BDCB8C8B081BQ26770355-0AB6A8F0-06B1-423D-908A-A0891146F81DQ26772092-D2404C3B-57D9-4A85-B93D-B20398900670Q26778014-482EDA7A-8942-4C4C-A972-5067D767BBBCQ26782089-75A508EC-18CF-432C-99C3-FA2EB7841913Q26795407-69693CBB-36C9-45FD-BA67-12149942346BQ26852368-9D25FA55-4157-4A70-96EF-7768A5085C22Q26860162-5705E92A-68DD-4413-8EB7-5DA0EF7B9D6DQ26992271-D8F59AC5-1EA1-4942-B5A1-3EA7EFA1736CQ27008193-8F5B4CE1-9716-4154-BEF6-CAC6E295F6DEQ27009581-2E6B37D3-9206-4C4D-AD37-3D3B937D46E8Q27027657-228F5C12-AD70-4074-A1B3-3964127EAF76Q27302798-8E99B055-5130-4F30-87F0-24EA9C04B361Q27314897-83314E80-0646-45D2-B717-4AEA8F3223CDQ27664845-E2041659-349B-4A3C-95D6-4FA641B8A9A5Q27673978-985C4F4D-2562-4CF2-A551-A42AFC2B416FQ27676643-1C65D8EA-D770-47A2-808D-C81CC8D291D4Q27678005-5225EA37-E653-4618-836D-0EB5E8A24404Q27679223-71F56687-8374-4F2A-8620-9933D0C228E3Q27687153-D50746D7-0074-4CC1-B0D9-FDA0887C66E3Q27693607-82877BCE-979B-4878-9680-36863B53AF6DQ27927980-674FB7C2-F655-48DE-AF73-97F40C232E19Q28082939-C557596B-484E-4793-8B71-62DAFEA77F6AQ28083290-0DB26661-4F17-4439-BC3C-CF57594F5236Q28083838-45D761FA-3B1B-41EF-B76F-EEEA0E26BC28Q28083951-118D2E40-544E-4247-AF52-CE553A77F5D4Q28303047-E833D758-D724-4C8F-84EB-E3A9FBF4B0DEQ28478754-BF1354A7-23B7-4230-97F8-6EF05CC0E6C1Q28542911-B0362289-167E-46BA-A2B9-91CCBD41881BQ28821280-45B1009E-05F3-4C3A-B649-A7E72D92CD9AQ28828761-E10EA242-C0E2-4C9E-8764-AA428C48B227Q28829240-F3CBA368-773A-43D9-B190-5B49B8E6A372Q28830393-5DACD60F-41ED-4BE2-B179-AF71662681DAQ28833550-411037C6-2FE5-4821-AFB3-4BC76007E982Q29039090-F1803053-04AC-4C82-B1D7-A93D9100AF70Q30224330-72A40469-4AAF-46D4-A978-3798A5D2E844Q30434397-D304994E-4AA0-49BD-9BBF-AE94AE1DEF5FQ30514293-419357D3-FC22-4510-B204-74FB71BA980BQ30551534-57764A5D-FDBF-42B1-BA23-D6E1EF9050DD
P2860
RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
RNA targeting therapeutics: mo ...... des as a therapeutic platform.
@ast
RNA targeting therapeutics: mo ...... des as a therapeutic platform.
@en
RNA targeting therapeutics: mo ...... des as a therapeutic platform.
@nl
type
label
RNA targeting therapeutics: mo ...... des as a therapeutic platform.
@ast
RNA targeting therapeutics: mo ...... des as a therapeutic platform.
@en
RNA targeting therapeutics: mo ...... des as a therapeutic platform.
@nl
prefLabel
RNA targeting therapeutics: mo ...... des as a therapeutic platform.
@ast
RNA targeting therapeutics: mo ...... des as a therapeutic platform.
@en
RNA targeting therapeutics: mo ...... des as a therapeutic platform.
@nl
P1476
RNA targeting therapeutics: mo ...... des as a therapeutic platform.
@en
P2093
C Frank Bennett
Eric E Swayze
P304
P356
10.1146/ANNUREV.PHARMTOX.010909.105654
P577
2010-01-01T00:00:00Z